Last reviewed · How we verify
NCT03833999: MOLID
Mode of Action of Ondansetron, a 5-HT Receptor 3 Antagonist, in Lactulose Induced Diarrhoea
Phase 4 trial testing Ondansetron 8mg in Motility Disorder of Intestine in 16 participants. Completed in 27 June 2019.
27 June 2019
Quick facts
| Lead sponsor | University of Nottingham |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 16 |
| Start date | 16 October 2018 |
| Primary completion | 27 June 2019 |
| Estimated completion | 27 June 2019 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Ondansetron 8mg — full drug profile →
- abdominal MRI
- Lactulose (LACTULOSE) — full drug profile →
- Placebo oral capsule
Conditions studied
- Motility Disorder of Intestine — all drugs for Motility Disorder of Intestine →
- Ondansetron — all drugs for Ondansetron →
- Small Bowel Water — all drugs for Small Bowel Water →
Sponsor
University of Nottingham
Who can join
18 and older, any sex, with Motility Disorder of Intestine or Ondansetron. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a double-blind, two period, two treatment crossover trial of ondansetron verses placebo studying the effects of ondansetron in the small and large bowel, specifically its effects on the amount of water in the gut, measured by MRI.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03833999
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ondansetron 8mg
Trials testing the same drug.
- NCT05844501 — Ondansetron for the Management of Atrial Fibrillation · Phase 4 · recruiting
- NCT06850740 — Efficacy of Co-Spinal Ondansetron In Inguinal Herniorrhaphy · NA · enrolling by invitation
- NCT06297499 — Ondansetron Use for Preventing Pruritus in Patients Undergoing Cesarean Section · Phase 1 · recruiting
- NCT06697782 — Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer · Phase 4 · completed
- NCT06153602 — Effectiveness of Nalbuphine as an Adjuvant to Subarachnoid Block on Postoperative Analgesia in TURP Surgery · NA · completed
Other University of Nottingham trials
Trials by the same sponsor.
- NCT07518381 — Medication Understanding in MS · not yet recruiting
- NCT07355556 — Technology Supported Improvement, Management and Prevention of Accidental Falls in Hospitals · not yet recruiting
- NCT07506408 — Randomised Study of Web-Based Auditory Training With Varying Perceptual and Cognitive Demands on Training Gains and Gene · NA · recruiting
- NCT07237529 — What is the Feasibility of Narrative Exposure Therapy (NET) for People Experiencing Psychosis? · NA · not yet recruiting
- NCT07237997 — Protein Supplementation During Dialysis (PROSED) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03833999 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Nottingham
- Last refreshed: 27 November 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03833999.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing